Companies
Reliance Industries
- Country
- India
- Ticker
- RELIANCE.NS
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| marine-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsepaefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | The company raised financing across multiple currencies and products in FY 2025-26, including a Samurai loan of JPY 91.9 billion (~$625 million), KSURE-supported untied facilities (~$500 million), and NEXI-supported untied facilities (~$600 million). | ril.com |
| Capacity | The Jamnagar complex has an aggregate refining capacity of 1.24 million barrels of oil per day. Additional capacities vary by site and product, e.g., the Vadodara Manufacturing Division has capacities for ethylene (300,000 TPA) and various other petrochemicals. | ril.com · scribd.com |
| Certification | RIL is Great Place to Work certified. Relicord is accredited by AABB and licensed by the FDA, Government of India. RIL was previously certified as a Responsible Care Company by the American Chemistry Council. | ril.com |
| Regulatory approval | In July 2024, RIL was granted approval by the United States to resume importing oil from Venezuela. The company also complies with various national regulatory rules, such as the Digital Personal Data Protection Act, 2023. | ril.com |
| Production site | Key sites include the Jamnagar refinery complex, the Vadodara Manufacturing Division (VMD), the Nagothane Manufacturing Division, and fields in the Krishna Godavari (KG D6) basin and Sohagpur coal bed methane fields. | ril.com |
| Headcount | 4,19,911 employees as of 2026. | ril.com |
| Revenue | ₹11,75,919 crore (US$124.0 billion) for FY 2025-26. | ril.com |
Independent sources: ril.com · scribd.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CO2 valorization via microalgae | marine-biotech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.